COIOSDeep risk insights through multi-disciplinary research across the globe
Girl is happy looking at her phone
Item refines Preprint · not peer-reviewed Added

Self-guided lifestyle app lowered LDL-cholesterol by 3.9% more than usual care

In a pragmatic online trial of 278 adults with LDL-cholesterol above target, a self-guided lifestyle app lowered LDL by 3.9% more than usual care at six months.

A pragmatic online trial randomised 278 adults with LDL-cholesterol above their risk-adapted target to usual care with or without a self-guided lifestyle application. At six months the adjusted between-group difference in relative LDL change was -3.9%. A fall of at least 10% was reached by 41.7% of app users and 23.8% of controls.

Why it is interesting: Structured lifestyle support is guideline-mandated but rarely delivered; this puts a figure on what a self-guided app adds.

Source
medRxiv, 16 September 2026
Paper
A self-guided digital health application for LDL-cholesterol reduction in adults with hypercholesterolaemia (The DIGICHOL randomised controlled trial)
Authors
Riepenhausen A, Ekerdt C, Meyer B, Jauch-Chara K
DOI
10.64898/2026.09.15.26363103
Type
Preprint
Design
Pragmatic online 1:1 randomised controlled trial, n = 278 adults with LDL above risk-adapted target, six-month follow-up
Verdict
Refines prior evidence
Driver
Innovation in treatment
Driver
Heart and stroke
Driver
Changing behaviour at scale
Abstract — the authors' own words, CC BY

Structured lifestyle modification is the guideline-mandated foundation of lipid management but is rarely delivered in routine care. We evaluated lipodia , a fully self-guided digital health application providing structured lifestyle support, in a pragmatic randomised controlled trial conducted online. Adults with LDL-cholesterol above their risk-adapted target (n = 278) were randomised 1:1 to usual care plus lipodia or usual care alone. After six months, lipodia significantly reduced LDL-cholesterol relative to usual care (adjusted between-group difference in relative change −3.9%; p = 0.029), with nearly twice as many users achieving a clinically meaningful reduction of at least 10% (41.7% versus 23.8%; p = 0.002). lipodia also significantly improved patient activation, non-HDL-cholesterol, and health-related quality of life, with high uptake, low attrition, and no adverse device effects. As a self-guided tool, lipodia provides a scalable and guideline-concordant means of delivering structured lifestyle support that is rarely available in routine care.

Other drivers in Tomorrow's world